|
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
|
3 Months Ended |
6 Months Ended |
|
Jan. 31, 2015
|
Jan. 31, 2014
|
Jan. 31, 2015
|
Jan. 31, 2014
|
| Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited) [Abstract] |
|
|
|
|
| Net sales |
$ 18,189 |
$ 15,096 |
$ 34,836 |
$ 30,626 |
| Cost of sales |
8,605 |
6,698 |
15,982 |
13,304 |
| Gross profit |
9,584 |
8,398 |
18,854 |
17,322 |
| Operating expenses |
|
|
|
|
| Research and development |
1,028 |
1,513 |
2,227 |
2,710 |
| Sales and marketing |
3,643 |
3,630 |
7,339 |
7,205 |
| Medical device excise tax |
116 |
115 |
244 |
240 |
| Exit costs |
657 |
514 |
719 |
514 |
| General and administrative |
2,942 |
3,003 |
5,970 |
5,638 |
| Total operating expenses |
8,386 |
8,775 |
16,499 |
16,307 |
| Operating income (loss) |
1,198 |
(377) |
2,355 |
1,015 |
| Other income (expense) |
|
|
|
|
| Investment income |
1 |
3 |
2 |
6 |
| Interest expense |
(14) |
0 |
(14) |
0 |
| Total other income (expenses) |
(13) |
3 |
(12) |
6 |
| Income (loss) from operations before provision (benefit) for income taxes |
1,185 |
(374) |
2,343 |
1,021 |
| Provision (benefit) for income taxes |
233 |
(149) |
623 |
312 |
| Net income (loss) |
952 |
(225) |
1,720 |
709 |
| Earnings (loss) per share: |
|
|
|
|
| Basic earnings (loss) per share (in dollars per share) |
$ 0.04 |
$ (0.01) |
$ 0.07 |
$ 0.03 |
| Diluted earnings (loss) per share (in dollars per share) |
$ 0.04 |
$ (0.01) |
$ 0.07 |
$ 0.03 |
| Basic weighted average common shares outstanding (in shares) |
25,364,574 |
25,309,641 |
25,352,279 |
25,301,830 |
| Diluted weighted average common shares outstanding (in shares) |
25,424,835 |
25,309,641 |
25,407,508 |
25,386,679 |
| Net income (loss) |
952 |
(225) |
1,720 |
709 |
| Foreign currency translation adjustment |
(1,311) |
(35) |
(1,816) |
140 |
| Comprehensive (loss) income |
$ (359) |
$ (260) |
$ (96) |
$ 849 |